Novel approaches to oral iron treatment
EHA Library. Moretti D. Jun 15, 2019; 273690
Diego Moretti
Diego Moretti
Contributions
Learning Objectives
THIS MANUSCRIPT IS PUBLISHED AS AN OFFICIAL SUPPLEMENT OF HEMASPHERE.

Martina U. Muckenthaler - Chair introduction

Systemic iron homeostasis is maintained by the iron-regulated peptide hormone hepcidin and its target receptor, the iron exporter ferroportin. The hepcidin/ferroportin regulatory axis prevents diseases of iron overload (ie, Hereditary hemochromatosis, thalassemia) or iron deficiency (ie, anemia). In this session, we will discuss pathologies underlying these frequent disorders and dissect mechanisms that cause functional or absolute iron overload or deficiency. We will explore novel approaches to oral iron treatment, the value of hepcidin as a diagnostic marker and how novel therapeutics just entering clinical trials modulate plasma iron availability via the hepcidin/ferroportin regulatory system. This session provides an exciting example for how knowledge derived from basic research can be translated into the clinic.

Learning goals of the article
The aim of this educational session is to generate novel insight into.
• frequent pathologies caused by a misregulation of the hepcidin/ferroportin system.
• novel approaches to oral iron treatment.
• diagnosis of iron-related disorders.

Learning goals of the presentation
After attending this lecture, the participant will be able to
• describe current and emerging therapeutic approaches for oral iron supplementation,
• select appropriate oral iron regimen based on patient iron status and history of side effects, and
• recognize factors affecting iron bioavailability from oral iron supplements.

By continuing to browse or by clicking “Accept Terms & all Cookies”, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies